Puma Biotechnology (PBYI) Cash from Financing Activities (2010 - 2026)

Puma Biotechnology has reported Cash from Financing Activities for 15 years, with the latest figure at -$11.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities changed 0.0% year-over-year to -$11.3 million; the trailing twelve-month figure through Mar 2026 stood at -$45.2 million (changed 0.04% YoY), and the FY2025 full-year result was -$45.2 million, down 33.54% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$11.3 million, roughly flat from -$11.3 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $9.8 million in Q1 2022, with the low at -$11.3 million in Q2 2024.
• Historically, Cash from Financing Activities has averaged -$7.1 million across 4 years, with a median of -$11.3 million in 2024.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities jumped 121650.0% — and 2025, when it dropped 1.33%.
• Puma Biotechnology's Cash from Financing Activities stood at $2.4 million in 2022, then tumbled by 566.1% to -$11.3 million in 2024, then slipped by 0.01% to -$11.3 million in 2025, then changed by 0.0% to -$11.3 million in 2026.
• The last three Cash from Financing Activities figures came in at -$11.3 million (Q1 2026), -$11.3 million (Q4 2025), and -$11.3 million (Q3 2025), per Business Quant data.